JP2022512703A5 - - Google Patents
Info
- Publication number
- JP2022512703A5 JP2022512703A5 JP2021520915A JP2021520915A JP2022512703A5 JP 2022512703 A5 JP2022512703 A5 JP 2022512703A5 JP 2021520915 A JP2021520915 A JP 2021520915A JP 2021520915 A JP2021520915 A JP 2021520915A JP 2022512703 A5 JP2022512703 A5 JP 2022512703A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- guide
- nos
- guide rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093281A JP2025138662A (ja) | 2018-10-16 | 2025-06-04 | 免疫療法のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746522P | 2018-10-16 | 2018-10-16 | |
| US62/746,522 | 2018-10-16 | ||
| US201862747037P | 2018-10-17 | 2018-10-17 | |
| US62/747,037 | 2018-10-17 | ||
| PCT/US2019/056399 WO2020081613A1 (en) | 2018-10-16 | 2019-10-15 | Compositions and methods for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093281A Division JP2025138662A (ja) | 2018-10-16 | 2025-06-04 | 免疫療法のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512703A JP2022512703A (ja) | 2022-02-07 |
| JP2022512703A5 true JP2022512703A5 (https=) | 2022-10-24 |
Family
ID=68502008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520915A Pending JP2022512703A (ja) | 2018-10-16 | 2019-10-15 | 免疫療法のための組成物および方法 |
| JP2025093281A Pending JP2025138662A (ja) | 2018-10-16 | 2025-06-04 | 免疫療法のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093281A Pending JP2025138662A (ja) | 2018-10-16 | 2025-06-04 | 免疫療法のための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210340530A1 (https=) |
| EP (1) | EP3867379A1 (https=) |
| JP (2) | JP2022512703A (https=) |
| KR (1) | KR20210091160A (https=) |
| CN (1) | CN113227374A (https=) |
| AU (1) | AU2019362879B2 (https=) |
| BR (1) | BR112021007025A2 (https=) |
| CA (1) | CA3116132A1 (https=) |
| CO (1) | CO2021006301A2 (https=) |
| IL (1) | IL282225A (https=) |
| MX (1) | MX2021004214A (https=) |
| PH (1) | PH12021550849A1 (https=) |
| SG (1) | SG11202103571XA (https=) |
| TW (1) | TW202035693A (https=) |
| WO (1) | WO2020081613A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021226363A1 (en) * | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| MX2023004822A (es) * | 2020-10-26 | 2023-05-10 | Arsenal Biosciences Inc | Loci de puerto seguro. |
| US20240026351A1 (en) * | 2020-10-30 | 2024-01-25 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting trac and uses thereof |
| MX2023006878A (es) | 2020-12-11 | 2023-07-31 | Intellia Therapeutics Inc | Composiciones y métodos para reducir el mhc de clase ii en una célula. |
| CR20230320A (es) | 2020-12-23 | 2023-10-23 | Intellia Therapeutics Inc | Composiciones y métodos para reducir los hla-a en una célula |
| WO2022140587A1 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying ciita in a cell |
| CN116848235A (zh) | 2020-12-30 | 2023-10-03 | 因特利亚治疗公司 | 工程化t细胞 |
| EP4288525A1 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Natural killer cell receptor 2b4 compositions and methods for immunotherapy |
| EP4288089A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy |
| CN117042793A (zh) | 2021-02-08 | 2023-11-10 | 因特利亚治疗公司 | 用于免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法 |
| CN117083292A (zh) * | 2021-04-02 | 2023-11-17 | 科济生物医药（上海）有限公司 | Cs1工程化细胞及其组合物 |
| JP2024534114A (ja) | 2021-08-24 | 2024-09-18 | インテリア セラピューティクス，インコーポレイテッド | 細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法 |
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| JP2024540723A (ja) | 2021-11-03 | 2024-11-01 | インテリア セラピューティクス，インコーポレーテッド | 免疫療法のためのｃｄ３８組成物及び方法 |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| EP4511397A1 (en) | 2022-04-19 | 2025-02-26 | Intellia Therapeutics, Inc. | Chimeric antigen receptor compositions and uses |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| AU2023293131A1 (en) | 2022-06-16 | 2024-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
| WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2024088401A1 (en) * | 2022-10-28 | 2024-05-02 | CorrectSequence Therapeutics Co., Ltd | Gene editing systems and methods for reducing immunogenicity and graft versus host response |
| WO2024186971A1 (en) | 2023-03-07 | 2024-09-12 | Intellia Therapeutics, Inc. | Cish compositions and methods for immunotherapy |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025049631A1 (en) * | 2023-08-28 | 2025-03-06 | Kyverna Therapeutics, Inc. | Allogeneic car-t cell therapies and manufacture thereof |
| WO2025077790A1 (en) * | 2023-10-11 | 2025-04-17 | Chengdu Ucello Biotechnology Co., Limited | Engineered immune cells and uses thereof |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137439A2 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| US9937207B2 (en) * | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| WO2015161276A2 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| US20150376586A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| ES2841274T3 (es) | 2014-08-04 | 2021-07-07 | Hutchinson Fred Cancer Res | Inmunoterapia con células T específica para WT-1 |
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| EP3274454B1 (en) * | 2015-03-25 | 2021-08-25 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| EP3277294B1 (en) * | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| EP3389677B1 (en) * | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| EP3423580A1 (en) * | 2016-03-04 | 2019-01-09 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| CN106191062B (zh) * | 2016-07-18 | 2019-06-14 | 广东华南疫苗股份有限公司 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| WO2018132479A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Modified t cells and methods of their use |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| EP3686275A4 (en) * | 2017-09-18 | 2021-09-29 | Edigene Inc. | GENE EDITING LYMPHOCYTE T AND RELATED USE |
| JP2020537515A (ja) * | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| SG11202004026QA (en) * | 2017-10-30 | 2020-05-28 | Pact Pharma Inc | Primary cell gene editing |
| CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
| CN107746831B (zh) * | 2017-11-07 | 2019-04-23 | 南京北恒生物科技有限公司 | 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法 |
| CN107828730B (zh) * | 2017-11-07 | 2019-04-30 | 南京北恒生物科技有限公司 | 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法 |
| MA52207A (fr) * | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| MX2020011254A (es) * | 2018-04-27 | 2020-11-12 | Crispr Therapeutics Ag | Celulas t car anti-bcma para agotamiento de celulas de plasma. |
| CN112752767A (zh) * | 2018-04-27 | 2021-05-04 | 克里斯珀医疗股份公司 | 细胞毒性t细胞耗竭的方法和组合物 |
-
2019
- 2019-10-15 CN CN201980082863.9A patent/CN113227374A/zh active Pending
- 2019-10-15 WO PCT/US2019/056399 patent/WO2020081613A1/en not_active Ceased
- 2019-10-15 EP EP19801126.4A patent/EP3867379A1/en active Pending
- 2019-10-15 CA CA3116132A patent/CA3116132A1/en active Pending
- 2019-10-15 MX MX2021004214A patent/MX2021004214A/es unknown
- 2019-10-15 SG SG11202103571XA patent/SG11202103571XA/en unknown
- 2019-10-15 BR BR112021007025-7A patent/BR112021007025A2/pt unknown
- 2019-10-15 KR KR1020217014333A patent/KR20210091160A/ko active Pending
- 2019-10-15 AU AU2019362879A patent/AU2019362879B2/en active Active
- 2019-10-15 JP JP2021520915A patent/JP2022512703A/ja active Pending
- 2019-10-16 TW TW108137354A patent/TW202035693A/zh unknown
-
2021
- 2021-04-11 IL IL282225A patent/IL282225A/en unknown
- 2021-04-15 PH PH12021550849A patent/PH12021550849A1/en unknown
- 2021-04-15 US US17/231,556 patent/US20210340530A1/en active Pending
- 2021-05-13 CO CONC2021/0006301A patent/CO2021006301A2/es unknown
-
2025
- 2025-06-04 JP JP2025093281A patent/JP2025138662A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512703A5 (https=) | ||
| JP7490704B2 (ja) | 遺伝子組換えにより内在性ｆｏｘｐ３遺伝子の発現が安定化されたｃｄ４ ｔ細胞を使用した自己免疫疾患の治療方法 | |
| US20200299661A1 (en) | Cpf1-related methods and compositions for gene editing | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| US20190262399A1 (en) | Compositions and methods for evaluating and modulating immune responses | |
| KR20230053591A (ko) | 조작된 근육 표적화 조성물 | |
| CN114144423B (zh) | 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症 | |
| TW202425951A (zh) | 脂質奈米顆粒藥物綴合物 | |
| US20230000912A1 (en) | Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof | |
| JP7479399B2 (ja) | 癌腫瘍に対するテーラード低免疫ナノ小胞送達系 | |
| JP2023085547A (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| JP2022519070A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| CN116096886A (zh) | 用于调节叉头框p3(foxp3)基因表达的组合物和方法 | |
| TW202425952A (zh) | 脂質奈米顆粒藥物綴合物 | |
| KR20200129959A (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| WO2024152937A1 (zh) | 靶向fgf2的基因编辑系统及其应用 | |
| US20220290157A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis | |
| CN114072518B (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
| JP2023548478A5 (https=) | ||
| US20090060889A1 (en) | Ii-RNAi involved Ii suppression in cancer immunotherapy | |
| EP4640830A1 (en) | Means and methods for safe and efficient gene editing in cells | |
| TW202535429A (zh) | 包含５＇ｕｔｒ－３＇ｕｔｒ組合的多核苷酸及其用途 | |
| WO2025088508A1 (en) | Means and methods for genetic modification of uba1 |